Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate

Authors

  • Jenny J. Ko Department of Medical Oncology, Abbotsford Cancer Centre, Abbotsford, BC, Canada
  • Julia Adams
  • Tara McMillan
  • Katherine Sunderland Data and Analytics, BC Cancer, Vancouver, BC
  • Jennifer Goulart Department of Radiation Oncology, BC Cancer – Victoria, Victoria, BC
  • Jennifer Rauw Department of Medical Oncology, BC Cancer – Victoria, Victoria, BC
  • Sunil Parimi Department of Medical Oncology, BC Cancer – Victoria, Victoria, BC

DOI:

https://doi.org/10.5489/cuaj.7802

Keywords:

small cell cancer of prostate;, survival outcomes

Abstract

Introduction: Unresectable and metastatic small cell carcinoma of the prostate (SCPC) is a rare and aggressive disease that is under-represented in clinical trials. We carried out a retrospective chart review of metastatic or unresectable SCPC patients at British Columbia (BC) Cancer centers, studying diagnosis and treatment patterns.

Methods: Drug-dispensing records from the six BC Cancer centers were obtained from 2002–2017. For each patient, information was collected on baseline information prior to therapy and for each line of treatment. Treatments at each line were compared regarding time to progression and overall survival by Kaplan-Meier curves.

Results: Forty-one patients received treatment; 65.6% had metastatic disease and 61% had pure small cell carcinoma. Median time from treatment to death was 10 months (95% confidence interval [CI] 6–16). Patients with initially prostate-confined disease had a better median overall survival (mOS) of 21 months (95% CI 13–34) compared to those with initially locally advanced (mOS 19 months, 95% CI 5–37) and metastatic disease (mOS 8 months, 95% CI 6–10) (log-rank p=0.0364). All patients received either cisplatin- or carboplatin-based combination chemotherapy as the first-line treatment and 36.7% received second-line therapy. Time to second-line therapy was eight months for those who presented with metastatic SCPC, compared to 13 months for those with initial non-metastatic SCPC.

Conclusions: This single-province, multi-institution cohort reports data on unresectable and metastatic SCPC and highlights the poor prognosis of this rare disease entity.

Downloads

Download data is not yet available.

Downloads

Published

2022-06-09

How to Cite

Ko, J. J., Adams, J., McMillan, T., Sunderland, K., Goulart, J., Rauw, J., & Parimi, S. (2022). Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate. Canadian Urological Association Journal, 16(11), E528–32. https://doi.org/10.5489/cuaj.7802

Issue

Vol. 16 No. 11 (2022): CUAJ November

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.